Social Media Ideas for Amylyx Pharmaceuticals

AMLX Stock Soars as Amylyx GLP-1 Drug Succeeds in Late-Stage Trial

Amylyx’s bet on a GLP-1 blocker pays off

A late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery...

Amylyx readies approval push after GLP-1 inhibitor halves blood sugar crashes in ph. 3 win

Amylyx Pharmaceuticals’ $35 million bet on the GLP-1 receptor antagonist avexitide appears to have paid off, with the molecule cutting the number of dangerous blood sugar crashes b...

Amylyx Plans FDA Filing After GLP-1 Drug Hits Trial Goals in Rare Metabolic Condition

Amylyx Pharmaceuticals’ avexitide led to statistically significant and clinically meaningful reductions in hypoglycemic events in patients with post-bariatric hypoglycemia (PBH). T...

Amyloidosis Continues To Fight Back

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer's Disease Drug Candidate “NTX-083”

AGC Inc. (Headquarters: Tokyo; President: Yoshinori Hirai; hereinafter “AGC”) highlights its end-to-end support capabilities as a small-molecule pharmaceutical CDMO as demonstrated...

Amylin analogs in the clinic: a deep dive 

Amylin analogs are in clinical trials to address metabolic diseases on their own as well as to enhance the effects of GLP-1 drugs. The post Amylin analogs in the clinic: a deep d...

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

<![CDATA[Beyond Amyloid, Part Two (of two): Delivery, Diagnostics and the Path to Combination Care]]>

Actimed gets back rights to wasting disease drug, ending $126M deal with Faraday

Actimed Therapeutics has brought the full rights to its wasting disease drug back in-house, securing “strategic control” over the asset but losing out on a shot at over $120 millio...

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

An Alzheimer’s Drug Cut Expected Cognitive Decline Roughly in Half. It Didn’t Target Amyloid

Researchers say the oral drug LM11A-31 slowed the decline of brain-network function in a small trial, pointing to a potential broader strategy for treating Alzheimer’s.

<![CDATA[FDA Approves Leqembi Iqlik Subcutaneous Injection for Early Alzheimer’s Disease]]>

Alnylam (ALNY) Q2 2026 Earnings Call Transcript

TTR franchise revenues topped $1 billion for first time as AMVUTTRA gains traction.

HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so farAnti...

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time...

Vogenx IPO Raises $81M for Trial in Metabolic Disease With No Approved Drugs

Vogenx’s mizagliflozin is heading into Phase 2b testing for post-bariatric hypoglycemia (PBH). Amylyx Pharmaceuticals and Recordati are developing injectable peptide drugs for this...

FDA Approves Ionis Pharma Drug, the First for Ultra-Rare Alexander Disease

Ionis Pharmaceuticals’ zilganersen, brand name Zanvastro, is the first disease-modifying therapy approved for the neurological disorder Alexander disease. While Ionis has experienc...

Royalty Pharma pens $425M deal for slice of sales on AstraZeneca’s ATTR drug

Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca...

Alnylam plunges as earnings deliver ‘one-two punch’

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor

A phase 2b lupus trial of Alumis’ envudeucitinib has missed its primary and secondary endpoints. But the biotech is still moving the TYK2 inhibitor into phase 3 in the autoimmune d...

ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Ther...

Initiation of treatment with subcutaneous administration opens the door to fully at-home dosing, similar to injectable diabetes and GLP-1 weight loss therapies

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding